

Fund Summary

OptiMix Global Emerging Markets Share

OneAnswer Frontier Personal Super

31 March 2026

Fund details

Investment manager	OptiMix
Fund code	MMF1786AU
Asset type	Equity Emerging Markets
Region	Global
Fund size	\$10.58 million as at 31 Mar 2026
Commencement date	15 Nov 2010
Distributions	Retained

Investment objective

The fund aims to achieve returns (before fees, charges and taxes) that exceed the MSCI Emerging Markets (Free) Index (\$A unhedged), over periods of five years or more.

Investment strategy

The fund invests predominantly in a diversified portfolio of shares in global emerging markets through a mix of managers. The fund is actively managed in accordance with the OptiMix Multi-manager investment process.

Minimum time horizon


5 years

Standard Risk Measure*

The Standard Risk Measure (SRM) is based on industry guidance to allow investors to compare funds that are expected to deliver a similar number of negative annual returns over any 20 year period. The SRM for this fund is shown below:



Asset allocation



Fund performance

As at 31 Mar 2026

	1 mth	3 mth	1 yr	3 yr	5 yr	7 yr	10 yr
	%	%	%	% pa	% pa	% pa	% pa
Total Return †	-8.65	-2.17	22.40	14.62	4.40	4.66	6.40
Benchmark ‡	-9.54	-2.80	17.87	13.99	5.92	7.14	9.06
Excess Return	0.89	0.63	4.53	0.63	-1.52	-2.48	-2.66

Calendar year returns	YTD	2025	2024	2023	2022
Total Return †	-2.17	21.69	6.95	-19.27	1.75
Benchmark ‡	-2.80	24.01	18.48	9.15	-14.33
Excess Return	0.63	-2.32	-11.53	-28.42	16.08

Top 10 holdings

Security	% of fund
Taiwan Semiconductor Manufactu	11.26%
Samsung Electronics Co., Ltd.	5.05%
Tencent Holdings Limited	4.52%
Alibaba Group Holding Limited	2.93%
Sk Hynix Inc.	1.86%
Sk Square Co., Ltd.	1.45%
Vista Energy, S.A.B. De C.V.	1.30%
Ase Technology Holding Co., Lt	1.23%
Contemporary Amperex Technolog	1.22%
Itau Unibanco Holding S.A.	1.11%
Total Top 10	31.93%

* For further information on Standard Risk Measures and the calculation methodology used, go to onepath.com.au/personal/performance/product-updates.aspx

† Returns quoted use the unit price which is calculated using the net asset values for the relevant month end. The prices shown may differ from the actual unit price if an investor is applying for or redeeming an investment. Actual unit prices will be confirmed following any transaction on an investor's investment. Please note that all returns are after the deduction of management fees and expenses and assumes all distributions are re-invested. Where applicable, management fees have been deducted at the highest entry fee option rate. No allowance has been made for entry or exit fees.

‡ Benchmark (MSCI EM NR AUD) returns should be used for indicative purposes only. These returns may not be a true indication of this Fund's performance against its investment objective.

Fund Summary

OptiMix Global Emerging Markets Share

OneAnswer Frontier Personal Super

31 March 2026

Market and portfolio review

Global equity markets recorded positive returns in the December quarter, with a broader participation in gains as investors rotated out of mega-cap technology and into cyclical and defensive stocks. Lifecycle outperformed due to positive stock selection in industrials, consumer staples, consumer discretionary and communication services, and overweight to materials. Pzena outperformed mainly from positive stock selection in IT. The OptiMix Emerging Markets cross investment outperformed its benchmark and significantly outperformed the MSCI ACWI Ex Aus index, driven by strong performance of TT International and Intrinsic Alphinity underperformed due to negative stock selection in IT, communication services and consumer discretionary. Arrowstreet underperformed due to negative stock selection in communication services and healthcare. Brown Advisory underperformed from negative stock selection in IT and consumer discretionary.

Future investment strategy

The Trust generally gains its investment exposure by investing in a well-diversified portfolio of international share investment managers. The Trust's investments generally provide exposure to stocks within the MSCI All Country World ex Australia Index (\$A). However, the Trust has the capacity to gain exposure to shares outside the index, such as emerging markets and unlisted shares. The Trust aims to be fully invested at all times with cash exposure not exceeding 10% for any length of time. The Trust is authorised to utilise approved derivative instruments subject to the specific restriction that derivative instruments cannot be used to gear the portfolio exposure. The underlying managers may utilise strategies for the management of currency exposure. It is the strategy of the Trust that part of the international currency exposure may be hedged. The Trust has the capacity to apply currency overlay to manage currency risk.

OnePath Funds Management Limited (ABN 21 003 002 800 AFSL 23 8342) and OnePath Custodians Pty Limited (ABN 12 008 508 496 AFSL 238346 RSE L0000673) are the issuers of this material. Except as described in the relevant Product Disclosure Statement (PDS), the issuers do not stand behind or guarantee the capital or performance of your investment. Your investment is subject to investment risk, including possible repayment delays and loss of income and principal invested.

This information is current as at 31 Mar 2026 with the commentary current for the most recent quarter end (eg. March, June, Sept or Dec) however in some cases may be applicable for the preceding month or quarter end. Updated information will be available free of charge by contact Client Services on 133 665. The information is of a general nature and does not take into account your personal needs, financial circumstances or objectives. Before acting on this information, you should consider the appropriateness of the information, having regard to your needs, financial circumstances and objectives. Past performance is not indicative of future performance. The future value of investments may rise and fall with changes in the market. You should read the relevant PDS available at onepath.com.au and consider whether that particular product is right for you before making a decision to acquire or continue to hold the product.